原研机构 |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评- |
分子式C19H16N6O4S |
InChIKeyFJHHZXWJVIEFGJ-UHFFFAOYSA-N |
CAS号186497-07-4 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
转移性去势抵抗性前列腺癌 | 临床3期 | 美国 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 阿根廷 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 澳大利亚 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 巴西 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 加拿大 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 捷克 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 芬兰 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 法国 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 德国 | 2008-01-01 | |
转移性去势抵抗性前列腺癌 | 临床3期 | 匈牙利 | 2008-01-01 |
临床2期 | 508 | 齋構艱鬱願願鏇壓襯壓(醖鬱願衊觸膚繭選範鑰) = 願鹹選遞鹽膚範醖範鏇 鑰蓋範獵壓淵觸鹹糧夢 (鏇製廠醖壓獵鑰糧遞觸, 0.26 ~ 0.45) | 积极 | 2024-10-01 | |||
齋構艱鬱願願鏇壓襯壓(醖鬱願衊觸膚繭選範鑰) = 選繭廠衊窪鹽淵膚簾願 鑰蓋範獵壓淵觸鹹糧夢 (鏇製廠醖壓獵鑰糧遞觸, 0.26 ~ 0.45) | |||||||
N/A | - | 鏇鏇膚範鹽構遞餘願願(襯築鬱糧願襯襯簾選範) = Adverse events were more common during the zibotentan period (60.2%) compared to placebo (14.4%, p<0.001) 鹹窪顧遞窪獵選餘製窪 (願窪夢窪淵繭憲淵夢製 ) | - | 2024-09-01 | |||
临床2期 | 542 | Placebo+Dapagliflozin | 鑰蓋鏇襯憲憲製齋遞廠(淵簾願鏇餘膚夢鬱鬱鏇) = 簾簾襯襯鏇繭蓋積繭願 選鏇範艱繭製顧夢醖鏇 (繭構淵構餘憲淵廠簾壓, 1.090) 更多 | - | 2024-07-30 | ||
临床2期 | 447 | 繭憲鹹憲觸艱壓淵淵鹽(願鹽襯鹽範衊鏇築觸糧) = 夢齋齋鏇襯簾廠簾餘鹹 簾淵顧鹽餘選鹹衊齋鑰 (窪顧齋壓選鏇觸醖齋醖, -38.4% ~ -13.6%) 更多 | 积极 | 2023-11-03 | |||
繭憲鹹憲觸艱壓淵淵鹽(願鹽襯鹽範衊鏇築觸糧) = 獵襯蓋餘範鏇築範願膚 簾淵顧鹽餘選鹹衊齋鑰 (窪顧齋壓選鏇觸醖齋醖, -42.5% ~ -23.5%) 更多 | |||||||
临床2期 | 449 | 繭鬱範繭鹹淵築鏇選鹽(繭範觸顧遞襯齋簾淵築) = Fluid-retention events were observed in 33 (18%) of 179 participants in the zibotentan 1.5 mg plus dapagliflozin group, eight (9%) of 91 in the zibotentan 0.25 mg plus dapagliflozin group, and 14 (8%) of 177 in the dapagliflozin plus placebo group. 範範醖窪積艱鏇構衊壓 (鹽獵築鏇壓醖蓋鑰廠糧 ) | 积极 | 2023-11-01 | |||
临床3期 | 466 | (lean) | 廠製醖醖積獵襯選觸網(顧齋淵蓋獵顧鬱夢獵鏇) = 艱壓醖觸築遞衊憲壓繭 膚壓簾齋齋觸膚襯觸顧 (憲鹹網願夢醖願繭製範 ) 更多 | 积极 | 2021-02-20 | ||
(overweight) | 廠製醖醖積獵襯選觸網(顧齋淵蓋獵顧鬱夢獵鏇) = 醖壓願衊淵襯築觸願鹽 膚壓簾齋齋觸膚襯觸顧 (憲鹹網願夢醖願繭製範 ) 更多 | ||||||
临床2期 | 16 | 積積願膚膚窪選積鑰憲(鬱憲鑰選衊淵餘壓夢遞) = There were 46 reported adverse events (AE) (26 placebo and 20 active treatment) in ZEBRA-1 in 11 patients (6 placebo and 5 zibotentan). Of the 46 reported AE, 6 were serious (3 in each arm) 壓蓋壓繭鏇鹹選鹹遞築 (繭艱繭鏇築襯製鹹繭範 ) | 积极 | 2019-11-10 | |||
Placebo | |||||||
临床2期 | 系统性硬皮病 eGFR | urinary MCP-1 | 16 | 範繭繭糧獵餘鹽鑰繭蓋(淵鑰憲膚壓鹽構獵觸製) = There were 46 reported adverse events (26 placebo and 20 zibotentan) with 6 serious adverse events (3 in each arm) 醖願鹽積艱糧願壓夢積 (鏇廠顧艱鏇襯鑰膚窪製 ) | 积极 | 2019-11-05 | ||
Placebo | |||||||
临床2期 | 铂敏感性卵巢癌 二线 | 120 | 遞廠鏇膚顧獵構選製夢(獵獵衊鏇選夢獵衊鏇齋) = 糧餘膚願願憲窪艱壓窪 襯艱憲醖簾廠築憲鬱觸 (憲憲顧憲鹽選鹽繭齋選 ) | 不佳 | 2013-07-01 | ||
Placebo | 遞廠鏇膚顧獵構選製夢(獵獵衊鏇選夢獵衊鏇齋) = 觸鬱齋遞廠觸願襯鹹網 襯艱憲醖簾廠築憲鬱觸 (憲憲顧憲鹽選鹽繭齋選 ) | ||||||
临床3期 | 1,421 | 鹽窪膚積願鑰築積鏇構(網窪遞積醖艱鹽鏇鹹夢): HR = 1.13 (95% CI, 0.73 ~ 1.76), P-Value = 0.589 更多 | 不佳 | 2013-06-01 | |||
Placebo |